REGN241220P755000
- 25.80
- +8.90+52.66%
Regeneron Pharmaceuticals Newsroom
Palantir, Tesla, and Other Stocks That Have Soared Past Wall Street's Price Targets
Weekly Buzz: Tech stocks hit high scores on ominous day
Market Mixed on Friday the 13th | Livestock
Regeneron Down 15.5% Year to Date: How to Play the Stock?
Thursday Ends in Index Declines | Wall Street Today
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Express News | B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Presents New And Updated Data For Odronextamab At ASH Annual Meeting
Kodiak Stock Rallies 32% After Jefferies Upgrades to Buy
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
Stocks With Best Odds of Risk-adjusted Returns Deserve Attention: Goldman Sachs
- Regeneron Announced Novel Combination Of Pozelimab And Cemdisiran Achieved Greater Control Of Intravascular Hemolysis In Patients With Paroxysmal Nocturnal Hemoglobinuria Vs Ravulizumab